Targeting the gene in Friedreich ataxia

被引:13
|
作者
Hebert, Michael D. [1 ]
机构
[1] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA
关键词
triplet repeat; neurodegenerative; HDAC inhibitors; DNA binding; frataxin;
D O I
10.1016/j.biochi.2007.12.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pathological expansions of GAA repeats in the first intron of the frataxin gene cause most cases of Friedreich ataxia, a progressively debilitating neurodegenerative disease. The disease is inherited in an autosomal recessive manner and the GAA repeats are suspected to form unusual non B-DNA conformations that decrease transcription and subsequently reduce levels of the encoded protein, frataxin. Recent work has shown that GAA repeats induce heterochromatin formation and silencing of the frataxin gene locus. Frataxin plays a crucial role in iron metabolism and detoxification and interacts with electron transport chain proteins. Clinical trials are currently underway to examine the efficacy of antioxidants in the treatment of Friedreich ataxia, but therapeutics designed to increase frataxin message levels are still in the developmental stages. This review will focus on the progress of potential treatment strategies for Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin message and protein. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1131 / 1139
页数:9
相关论文
共 50 条
  • [31] Hypertrophic cardiomyopathy in Friedreich's ataxia
    Fayssoil, A.
    Nardi, O.
    Orlikowski, D.
    Annane, D.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 127 (03) : E122 - E123
  • [32] Erythropoietin and Friedreich Ataxia: Time for a Reappraisal?
    Boesch, Sylvia
    Indelicato, Elisabetta
    FRONTIERS IN NEUROSCIENCE, 2019, 13
  • [33] Effect of diazoxide on Friedreich ataxia models
    Santoro, Antonella
    Virmouni, Sara Anjomani
    Paradies, Eleonora
    Coa, Valentina L. Villalobos
    Al-Mahdawi, Sahar
    Khoo, Mee
    Porcelli, Vito
    Vozza, Angelo
    Perrone, Mara
    Denora, Nunzio
    Taroni, Franco
    Merla, Giuseppe
    Palmieri, Luigi
    Pook, Mark A.
    Marobbio, Carlo M. T.
    HUMAN MOLECULAR GENETICS, 2018, 27 (06) : 992 - 1001
  • [34] Herzbeteiligung bei Friedreich-AtaxieHeart involvement in Friedreich’s ataxia
    F. Weidemann
    F. Scholz
    C. Florescu
    D. Liu
    K. Hu
    S. Herrmann
    G. Ertl
    S. Störk
    Herz, 2015, 40 : 85 - 90
  • [35] Therapeutic strategies in Friedreich's Ataxia
    Richanison, Timothy E.
    Kelly, Heather N.
    Yu, Amanda E.
    Simpkins, James W.
    BRAIN RESEARCH, 2013, 1514 : 91 - 97
  • [36] Friedreich Ataxia: Multidisciplinary Clinical Care
    Lynch, David R.
    Schadt, Kim
    Kichula, Elizabeth
    McCormack, Shana
    Lin, Kimberly Y.
    JOURNAL OF MULTIDISCIPLINARY HEALTHCARE, 2021, 14 : 1645 - 1658
  • [37] Identification of telomere dysfunction in Friedreich ataxia
    Sara Anjomani Virmouni
    Sahar Al-Mahdawi
    Chiranjeevi Sandi
    Hemad Yasaei
    Paola Giunti
    Predrag Slijepcevic
    Mark A. Pook
    Molecular Neurodegeneration, 10
  • [38] Emerging therapies in Friedreich's Ataxia
    Zesiewicz, Theresa A.
    Hancock, Joshua
    Ghanekar, Shaila D.
    Kuo, Sheng-Han
    Dohse, Carlos A.
    Vega, Joshua
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2020, 20 (12) : 1215 - 1228
  • [39] Identification of telomere dysfunction in Friedreich ataxia
    Virmouni, Sara Anjomani
    Al-Mahdawi, Sahar
    Sandi, Chiranjeevi
    Yasaei, Hemad
    Giunti, Paola
    Slijepcevic, Predrag
    Pook, Mark A.
    MOLECULAR NEURODEGENERATION, 2015, 10
  • [40] Cardiomyopathy in Friedreich Ataxia: Clinical Findings and Research
    Payne, R. Mark
    Wagner, Gregory R.
    JOURNAL OF CHILD NEUROLOGY, 2012, 27 (09) : 1179 - 1186